Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, multicenter, randomized, evaluation committee-blinded study to assess the efficacy of topical omiganan 1.0 percent gel in preventing local catheter site infections/colonization in patients undergoing central venous catheterization

Next Previous
Trial Profile

A phase 3, multicenter, randomized, evaluation committee-blinded study to assess the efficacy of topical omiganan 1.0 percent gel in preventing local catheter site infections/colonization in patients undergoing central venous catheterization

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omiganan (Primary) ; Povidone iodine
  • Indications Bacterial infections; Catheter infections
  • Focus Registrational; Therapeutic Use
  • Acronyms CLIRS
  • Sponsors Cadence Pharmaceuticals

Most Recent Events

  • 12 Sep 2009 Results reported at ICAAC 2009.
  • 18 Aug 2009 Additional trial location (Germany) identified as reported by ClinicalTrials.gov.
  • 15 Sep 2008 Results are expected in the first quarter of 2009, according to a Cadence Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top